<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03259919</url>
  </required_header>
  <id_info>
    <org_study_id>220800</org_study_id>
    <nct_id>NCT03259919</nct_id>
  </id_info>
  <brief_title>Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study</brief_title>
  <acronym>pilPregMet</acronym>
  <official_title>Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of metformin on pregnancy complications and pregnancy outcome in
      the II. and III. trimester of pregnancy in women with polycystic ovary syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2000</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dehydroepiandrosterone sulfate (DHEAS)</measure>
    <time_frame>up to delivery</time_frame>
    <description>(µmol/l) Analysed in serum, from venous blood samples from the mother and venous and arterial umbilical cord blood (separately) collected within 1 h of birth. Measured using a competitive immunoassay on an Immulite 2000 analyser using the reagents and calibrators supplied by the manufacturer (Diagnostic Products Corp., USA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Androstenedione</measure>
    <time_frame>up to delivery</time_frame>
    <description>Analysed in serum, from venous blood samples from the mother and venous and arterial umbilical cord blood (separately) collected within 1 h of birth. measured by a double antibody technique on an Elecsys 2010 analyser (Roche Diagnostics GmbH, Germany) using reagents and calibrators supplied by the manufacturer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testosterone</measure>
    <time_frame>up to delivery</time_frame>
    <description>Analysed in serum, from venous blood samples from the mother and venous and arterial umbilical cord blood (separately) collected within 1 h of birth. measured by a double antibody technique on an Elecsys 2010 analyser (Roche Diagnostics GmbH, Germany) using reagents and calibrators supplied by the manufacturer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sex hormone binding globulin (SHBG)</measure>
    <time_frame>up to delivery</time_frame>
    <description>(nmol/l) Analysed in serum, from venous blood samples from the mother and venous and arterial umbilical cord blood (separately) collected within 1 h of birth. Measured using a competitive immunoassay on an Immulite 2000 analyser using the reagents and calibrators supplied by the manufacturer (Diagnostic Products Corp., USA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free testosterone index</measure>
    <time_frame>up to delivery</time_frame>
    <description>Calculated as total testosterone divided by SHBG and multiplied by a factor of 100. SHBG measured using a competitive immunoassay on an Immulite 2000 analyser using the reagents and calibrators supplied by the manufacturer (Diagnostic Products Corp., USA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of pregnancy complications</measure>
    <time_frame>up to 6 weeks post partum</time_frame>
    <description>Gestational diabetes (GDM) defined according to World Health Organization (1998) criteria, i.e. 2 h plasma glucose values ≥7.8 mmol/l during an Oral Glucose Tolerance Test (OGTT) with 75 g. Uncomplicated GDM treated with dietary advice only was not ranked among the complications in this study. Pre-eclampsia defined as a blood pressure ≥140/90mmHg with concomitant albuminuria ≥0.3 g/24 h measured on two separate occasions after gestational week 20. Premature delivery was defined as delivery before gestational week 37 + 0 according to an estimated date of delivery, based on mid-trimester ultrasound scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - gestational age</measure>
    <time_frame>after delivery</time_frame>
    <description>Gestational age at birth (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - gestational length</measure>
    <time_frame>after delivery</time_frame>
    <description>Gestational length (cm) measured at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - head circumference</measure>
    <time_frame>after delivery</time_frame>
    <description>Head circumference (cm) measured at birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - birthweight</measure>
    <time_frame>after delivery</time_frame>
    <description>Birthweight (g) measured at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - placental weight</measure>
    <time_frame>after delivery</time_frame>
    <description>Placental weight (g) measured at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - Agpar score at 5 minutes</measure>
    <time_frame>after delivery</time_frame>
    <description>Apgar score at 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - Agpar score at 10 minutes</measure>
    <time_frame>after delivery</time_frame>
    <description>Apgar score at 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - umbilical artery pH</measure>
    <time_frame>after delivery</time_frame>
    <description>Umbilical artery pH measured in umbilical artery blood, immediately after delivery on a Rapidlab 248pH/Blood Gas Analyzer, using reagents and calibrators supplied by the manufacturer (Bayer Corp., USA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 850 mg x 2 daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet x 2 daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>metformin from Weifa 425 mg / tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo from Weifa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis polycystic ovary syndrome (PCOS ) before pregnancy

          -  BMI 27-40 kg/m2

          -  Human chorionic gonadotropin, beta subunit (HCG-beta) verified pregnancy week 5-8

          -  At least one of the following criteria: (1) serum testosteron &gt; 2,5 nmol/L; (2) Sex
             hormone binding globulin (SHBG) &lt; 30 nmol; (3) Fasting C-peptid &gt; 1,0 nmol/L; (4)
             Menstrual disturbances: oligo-/amenorrhea or metrorrhagia; (5) Hirsutism

        Exclusion Criteria:

          -  known liver disease or ALAT &gt; 60 IU/L

          -  S-creatinin &gt; 130 micromol/L

          -  diabetes mellitus

          -  alcohol or drug abuse

          -  peroral steroid treatment (except inhalation steroids)

          -  use of cimetidine, anticoagulant, erythromycin or other macrolides

          -  not suitable for other reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven M Carlsen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departments of Obstetrics and Gynecology and Endocrinology, St. Olav's Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004 Aug;19(8):1734-40. Epub 2004 Jun 3.</citation>
    <PMID>15178665</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>September 17, 2017</last_update_submitted>
  <last_update_submitted_qc>September 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Pregnancy outcome</keyword>
  <keyword>Androgens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

